$13.04
+0.16 (+1.24%)
Open$13.00
Previous Close$12.88
Day High$13.41
Day Low$12.62
52W High$16.76
52W Low$9.85
Volume—
Avg Volume101.4K
Market Cap417.41M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+106.1% upside
Current
$13.04
$13.04
Target
$26.87
$26.87
$21.20
$26.87 avg
$38.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 792.56M | 838.23M | 726.24M |
| Net Income | 29.18M | 25.09M | 21.12M |
| Profit Margin | 3.7% | 3.0% | 2.9% |
| EBITDA | 33.32M | 33.92M | 33.30M |
| Free Cash Flow | 24.79M | 28.65M | 30.31M |
| Rev Growth | +7.9% | +14.3% | -7.3% |
| Debt/Equity | 0.15 | 0.16 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |